These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26195467)

  • 1. Performance Requirements to Achieve Cost-Effectiveness of Point-of-Care Tests for Sepsis Among Patients with Febrile Illness in Low-Resource Settings.
    Penno EC; Crump JA; Baird SJ
    Am J Trop Med Hyg; 2015 Oct; 93(4):841-9. PubMed ID: 26195467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Surveillance for Bloodstream Infections for Sepsis Management in Low-Resource Settings.
    Penno EC; Baird SJ; Crump JA
    Am J Trop Med Hyg; 2015 Oct; 93(4):850-60. PubMed ID: 26175032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel electronic algorithm using host biomarker point-of-care tests for the management of febrile illnesses in Tanzanian children (e-POCT): A randomized, controlled non-inferiority trial.
    Keitel K; Kagoro F; Samaka J; Masimba J; Said Z; Temba H; Mlaganile T; Sangu W; Rambaud-Althaus C; Gervaix A; Genton B; D'Acremont V
    PLoS Med; 2017 Oct; 14(10):e1002411. PubMed ID: 29059253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic considerations support C-reactive protein testing alongside malaria rapid diagnostic tests to guide antimicrobial therapy for patients with febrile illness in settings with low malaria endemicity.
    Lubell Y; Chandna A; Smithuis F; White L; Wertheim HFL; Redard-Jacot M; Katz Z; Dondorp A; Day N; White N; Dittrich S
    Malar J; 2019 Dec; 18(1):442. PubMed ID: 31878978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the Impact and Cost-Effectiveness of Biomarker Tests as Compared with Pathogen-Specific Diagnostics in the Management of Undifferentiated Fever in Remote Tropical Settings.
    Lubell Y; Althaus T; Blacksell SD; Paris DH; Mayxay M; Pan-Ngum W; White LJ; Day NP; Newton PN
    PLoS One; 2016; 11(3):e0152420. PubMed ID: 27027303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.
    Westwood M; Ramaekers B; Whiting P; Tomini F; Joore M; Armstrong N; Ryder S; Stirk L; Severens J; Kleijnen J
    Health Technol Assess; 2015 Nov; 19(96):v-xxv, 1-236. PubMed ID: 26569153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future.
    Schultz MJ; Dunser MW; Dondorp AM; Adhikari NK; Iyer S; Kwizera A; Lubell Y; Papali A; Pisani L; Riviello BD; Angus DC; Azevedo LC; Baker T; Diaz JV; Festic E; Haniffa R; Jawa R; Jacob ST; Kissoon N; Lodha R; Martin-Loeches I; Lundeg G; Misango D; Mer M; Mohanty S; Murthy S; Musa N; Nakibuuka J; Serpa Neto A; Nguyen Thi Hoang M; Nguyen Thien B; Pattnaik R; Phua J; Preller J; Povoa P; Ranjit S; Talmor D; Thevanayagam J; Thwaites CL;
    Intensive Care Med; 2017 May; 43(5):612-624. PubMed ID: 28349179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
    Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
    Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis protocol of the Smart Triage program: A point-of-care digital triage platform for pediatric sepsis in Eastern Uganda.
    Li ECK; Grays S; Tagoola A; Komugisha C; Nabweteme AM; Ansermino JM; Mitton C; Kissoon N; Khowaja AR
    PLoS One; 2021; 16(11):e0260044. PubMed ID: 34788338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.
    Stevenson M; Pandor A; Martyn-St James M; Rafia R; Uttley L; Stevens J; Sanderson J; Wong R; Perkins GD; McMullan R; Dark P
    Health Technol Assess; 2016 Jun; 20(46):1-246. PubMed ID: 27355222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey.
    Lubell Y; Staedke SG; Greenwood BM; Kamya MR; Molyneux M; Newton PN; Reyburn H; Snow RW; D'Alessandro U; English M; Day N; Kremsner P; Dondorp A; Mbacham W; Dorsey G; Owusu-Agyei S; Maitland K; Krishna S; Newton C; Pasvol G; Taylor T; von Seidlein L; White NJ; Binka F; Mills A; Whitty CJ
    PLoS One; 2011 Feb; 6(2):e17439. PubMed ID: 21390277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The financial and clinical implications of adult malaria diagnosis using microscopy in Kenya.
    Zurovac D; Larson BA; Akhwale W; Snow RW
    Trop Med Int Health; 2006 Aug; 11(8):1185-94. PubMed ID: 16903882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electronic clinical decision algorithms for the integrated primary care management of febrile children in low-resource settings: review of existing tools.
    Keitel K; D'Acremont V
    Clin Microbiol Infect; 2018 Aug; 24(8):845-855. PubMed ID: 29684634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
    Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
    Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
    Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
    Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.
    Burchardi H; Schneider H
    Pharmacoeconomics; 2004; 22(12):793-813. PubMed ID: 15294012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
    Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
    J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.